查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1931278

PMO偶聯物市場按產品類型、應用、最終用戶、遞送方式和分子類型分類，全球預測，2026-2032年

PMO Conjugates Market by Product Type, Application, End User, Delivery Mode, Molecule Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，PMO 共軛物市場價值將達到 1.3285 億美元，到 2026 年將成長至 1.5241 億美元，到 2032 年將達到 3.4284 億美元，複合年成長率為 14.50%。

主要市場統計數據
基準年 2025 1.3285億美元
預計年份：2026年 1.5241億美元
預測年份：2032年 3.4284億美元
複合年成長率 (%) 14.50%

PMO偶聯物的策略概述：重點關注治療潛力、遞送挑戰、監管趨勢和商業化管道，以相關人員。

磷醯二胺嗎啉寡聚物(PMO) 偶聯物的出現代表了反義療法標靶遞送領域的一項突破，它兼具分子精準性和高組織結合力。研發人員和相關人員正日益關注偶聯策略如何能夠在維持寡核苷酸活性的同時，改善其藥物動力學和細胞攝取。同時，臨床計畫也持續改善病患入組標準和終點設計，以期證實其具有顯著的治療效果，尤其是在傳統小分子和生技藥品療效有限的特定基因族群中。

新的技術、監管和商業性轉折點將重塑PMO偶聯療法的全球開發和患者獲取格局。

PMO偶聯物領域正經歷變革性的轉折點，這主要得益於科學創新、不斷變化的監管環境以及支付方和患者期望的轉變。胜肽和抗體偶聯化學的進步正在拓展工具箱，以改善細胞攝取、核內體逃脫和組織選擇性，從而提高在難以到達的組織中實現持續靶向結合的可能性。同時，分析表徵和基於平台的生產技術的改進正在簡化CMC流程，使開發人員能夠從客製化開發轉向支援更廣泛臨床開發的標準化流程。

2025年美國關稅政策預期變化對專案管理辦公室（PMO）整合開發公司的供應鏈、成本結構和策略採購決策的影響

貿易政策和關稅制度的預期變化可能會對複雜生技藥品和寡核苷酸偶聯物的原料採購、試劑成本和全球供應鏈經濟產生重大影響。因此，開發PMO偶聯物的公司應評估關稅結構變化對供應商選擇、庫存策略和替代生產安排的影響。特別是，提高特殊試劑和中間體組件的進口關稅可能會促使關鍵獎勵的近岸外包或關鍵投入品的雙重採購，從而減輕單一國家關稅波動的影響。

詳細的細分分析重點闡述了產品、應用、最終用戶、給藥途徑和分子類型對研發重點和商業化路徑的影響

了解這種細分市場的細微差別對於在PMO偶聯物領域優先進行研發工作和進行商業性定位至關重要。根據產品類型，抗體-PMO偶聯物和胜肽-PMO偶聯物的研發路徑有顯著差異。基於抗體的構建體往往專注於透過受體介導靶向特定細胞群，而胜肽偶聯物則可以進行模組化設計，以最佳化組織滲透性遞送和細胞攝取。按應用領域分類，治療重點集中在神經肌肉疾病、腫瘤和罕見遺傳疾病，其中神經肌肉疾病的適應症進一步細分為Duchenne氏肌肉失養症和脊髓性肌肉萎縮症。在Duchenne氏肌肉失養症中，治療方案的設計通常在跳躍外顯子療法和無義突變標靶療法之間有所不同，每種療法都有不同的患者納入標準和監管先例。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和比較優勢將決定臨床檢測實施和供應的韌性

區域趨勢對PMO偶聯物的臨床開發策略、供應鏈設計和報銷方式有顯著影響。在美洲，完善的臨床試驗基礎設施和對創新療法較為開放的法規環境，有利於快速概念驗證研究，並與支付方在基於價值的報銷管道方面進行密切合作。在該地區運營的申辦方通常會優先考慮早期與監管機構的溝通以及真實世界證據計劃，以支持核准後的廣泛應用。同時，歐洲、中東和非洲的市場環境較為複雜，各司法管轄區的監管協調程度不一，定價框架也存在差異，因此需要製定複雜的市場進入策略和量身定做的證據方案，以適應各國特定的衛生技術評估（HTA）流程。

競爭考察與合作並存的企業級洞察，揭示了PMO共軛生態系統中相關人員所採用的許可、夥伴關係和製造策略。

在PMO偶聯物生態系統中，企業策略融合了競爭差異化和合作夥伴關係模式。早期創新者和學術衍生公司通常利用深厚的生物學知識和靈活的實驗方法來主導藥物發現和概念驗證數據，從而確定目標的有效性。這些機構通常依賴與大型製藥企業或專業的合約開發和生產組織（CDMO）的合作，以擴大其CMC（化學、生產和品管）營運規模，並推進到後期臨床開發階段。大型生物製藥公司提供商業性專業知識、監管經驗和成熟的分銷網路。這些優勢可以與創新的偶聯平台結合，從而加速患者獲得藥物。

產業領導者可以採取哪些明確步驟來最佳化其PMO偶聯物產品組合的研發產品線、供應鏈、監管回應和商業化？

產業領導者應充分發揮PMO偶聯物的潛力，採取一系列切實可行的優先事項，將科學潛力與商業性可行性結合。首先，應優先考慮平台穩健性，投資於具有穩定分析性能和可擴展生產能力的連接子和偶聯化學方法。這將降低下游監管的複雜性，並提高供應的可預測性。其次，應設計臨床方案，在傳統療效終點之外，納入可操作的持久性指標和患者報告獲益，儘早為監管機構和支付方提供證據，並促進醫保報銷談判。

調查方法詳情：採用混合方法，結合定性和定量研究方法、專家檢驗和數據三角測量，以支持研究結果和建議。

本分析基於嚴謹的混合方法，結合了定性專家研究和權威第二手資料的定量綜合分析。一手資訊來源包括對資深研發主管、生產專家、臨床研究人員以及在寡核苷酸和偶聯物項目方面擁有直接經驗的監管顧問進行的結構化訪談。這些見解與對同行評審文獻、監管指導文件和技術白皮書的深入審查相結合，以確保與當前的科學知識和先例保持一致。

一份策略建議綜合報告，重點闡述了影響PMO偶聯物應用、投資者興趣和長期永續性的臨床、營運和政策因素。

總之，PMO偶聯物正處於一個轉折點，標靶化和遞送方面的科學進步與不斷變化的監管政策和生產製造方面的營運創新相交。如果申辦者能夠使化學決策、臨床策略和供應鏈韌性與監管機構和支付者的期望保持一致，那麼這種療法將為解決神經肌肉疾病、腫瘤和罕見遺傳疾病領域尚未滿足的醫療需求提供極具吸引力的機會。從產品類型、適應症、最終用戶、給藥方式和分子類型等方面進行策略性細分，有助於確定投資重點，並針對最有前景的患者群體最佳化研發管道。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的PMO偶聯物市場

  • 抗體PMO偶聯物
  • 胜肽PMO綴合物

9. 按應用分類的PMO共軛物市場

  • 神經肌肉疾病
    • Duchenne氏肌肉失養症
    • 脊髓性肌肉萎縮症
  • 腫瘤學
  • 罕見遺傳疾病

第10章 依最終用戶分類的PMO共軛物市場

  • 學術和研究機構
  • CRO（受託研究機構）
  • 製藥和生物技術公司

11. 依交付方式分類的PMO偶聯物市場

  • 肌肉內注射
  • 靜脈注射
  • 皮下注射

12. 依分子類型分類的PMO偶聯物市場

  • 多功能型
  • 單功能類型

第13章 各地區PMO共軛物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的PMO共軛物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國PMO共軛物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國PMO共軛市場

第17章：中國的PMO共軛市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Agilent Technologies, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Aurigene Pharmaceutical Services Ltd.
  • Avidity Biosciences, Inc.
  • Bio-Synthesis, Inc.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • Creative Biogene Co., Ltd.
  • Epichem Pty Ltd
  • Gene Tools, LLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • NJ Bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics, Inc.
  • Roche Holding AG
  • Sarepta Therapeutics, Inc.
  • Wave Life Sciences Ltd.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-7B550E008E02

The PMO Conjugates Market was valued at USD 132.85 million in 2025 and is projected to grow to USD 152.41 million in 2026, with a CAGR of 14.50%, reaching USD 342.84 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 132.85 million
Estimated Year [2026] USD 152.41 million
Forecast Year [2032] USD 342.84 million
CAGR (%) 14.50%

Strategic overview of PMO conjugates highlighting therapeutic potential, delivery challenges, regulatory dynamics and commercialization pathways for stakeholders

The emergence of phosphorodiamidate morpholino oligomer (PMO) conjugates represents a pivotal advance in the targeted delivery of antisense therapies, blending molecular precision with enhanced tissue engagement. Developers and stakeholders are increasingly focused on how conjugation strategies transform pharmacokinetics and cellular uptake while preserving oligonucleotide activity. In parallel, clinical programs are refining patient selection criteria and endpoint design to demonstrate meaningful therapeutic benefit in genetically defined populations, particularly where conventional small molecules and biologics have limited efficacy.

Transitioning from laboratory validation to clinical translation requires coordinated attention to chemistry, manufacturing, controls, and regulatory interactions. Manufacturing scale-up presents unique demands because conjugation chemistries and linker technologies can introduce new analytical and stability considerations that influence lot-to-lot consistency. As a result, sponsors are adopting modular development plans that integrate analytical method development, bridging studies, and early engagement with regulatory authorities to de-risk pivotal programs. Taken together, these dynamics position PMO conjugates as a high-priority modality for precision therapeutics, while underscoring the need for cross-functional strategies that align R&D, regulatory, and commercial planning.

Emerging technological, regulatory and commercial inflection points reshaping the development and patient access landscape for PMO conjugate therapeutics globally

The PMO conjugate landscape is undergoing transformative shifts driven by convergence of scientific innovation, evolving regulatory frameworks, and changing payer and patient expectations. Advances in peptide and antibody conjugation chemistries have expanded the toolbox for improving cellular uptake, endosomal escape, and tissue selectivity, thereby elevating the probability of achieving durable target engagement in hard-to-reach tissues. At the same time, improvements in analytical characterization and platform-based manufacturing are streamlining CMC pathways, enabling sponsors to move from bespoke, case-by-case development toward more standardized processes that support broader clinical development.

Meanwhile, regulatory authorities are demonstrating greater familiarity with oligonucleotide modalities and are setting clearer expectations around toxicology, biodistribution, and long-term safety monitoring. This regulatory clarity is reducing uncertainty for clinical trial design and post-approval commitments, which in turn encourages greater investment in late-stage programs. Commercial models are also adapting: payers and health systems are increasingly weighing real-world evidence and durable benefit when assessing value, prompting sponsors to embed pragmatic outcomes measures and evidence-generation plans early in development. Because these shifts are interdependent, stakeholders that adopt integrated strategies across R&D, regulatory, manufacturing, and market access are positioned to capitalize on accelerating technological and policy momentum.

Projected implications of evolving United States tariff policies in 2025 on supply chains, cost structures, and strategic sourcing decisions for PMO conjugate developers

Anticipated changes in trade policy and tariff regimes can materially influence raw material sourcing, reagent costs, and the economics of global supply chains for complex biologics and oligonucleotide conjugates. Companies developing PMO conjugates should therefore evaluate how altered tariff structures may affect supplier selection, inventory strategies, and back-up manufacturing arrangements. In particular, higher import duties on specialty reagents or intermediate components can incentivize nearshoring of critical steps or the dual-sourcing of key inputs to mitigate exposure to single-country tariff shifts.

Beyond direct cost implications, tariffs influence strategic decisions about where to locate clinical manufacturing and fill-finish operations to preserve regulatory alignment and expedite investigational material supply. In this context, organizations are increasingly conducting scenario planning to understand how tariff changes interact with currency volatility, lead times, and the availability of qualified vendor capacity. By adopting a proactive approach to supply chain mapping and contract language, sponsors can maintain continuity of clinical programs and commercial launches even as trade policy evolves. This emphasizes the importance of cross-functional teams that regularly reassess supplier risk, contractual flexibility, and inventory buffers in light of potential policy changes.

Deep segmentation intelligence revealing how product, application, end user, delivery mode and molecule type influence development priorities and commercialization routes

A nuanced understanding of segmentation is essential to prioritize development efforts and commercial positioning across the PMO conjugate landscape. Based on product type, development pathways diverge significantly between antibody PMO conjugates and peptide PMO conjugates; antibody-based constructs often emphasize receptor-mediated targeting to specific cell populations, whereas peptide conjugates can be tailored for tissue-penetrant delivery and modular optimization of cellular uptake. Based on application, therapeutic priorities concentrate on neuromuscular diseases, oncology, and rare genetic disorders, with neuromuscular indications further differentiated into Duchenne muscular dystrophy and spinal muscular atrophy. Within Duchenne muscular dystrophy, program design commonly bifurcates between exon skipping therapies and approaches targeting nonsense mutations, each with distinct patient selection criteria and regulatory precedent.

Based on end user, development and translation pathways are shaped by the distinct incentives and capabilities of academic and research institutes, contract research organizations, and pharmaceutical and biotechnology companies; academic centers frequently drive early discovery and mechanistic studies, CROs enable scalable clinical development operations, and industry sponsors focus on late-stage evidence generation and market access. Based on delivery mode, clinical strategies reflect differences among intramuscular, intravenous, and subcutaneous administration, where route selection influences dosing frequency, patient convenience, and infrastructure requirements for trials and commercial distribution. Finally, based on molecule type, the field distinguishes between multi functional and single functional constructs, with multi functional molecules offering combinatorial benefits for targeting or activity and single functional designs emphasizing simplicity and manufacturability. Integrating these segmentation lenses allows sponsors to tailor preclinical models, CMC investments, and clinical endpoints to the most relevant patient populations and commercial pathways.

Regional dynamics and comparative advantages across the Americas, Europe Middle East & Africa and Asia-Pacific that determine clinical trial deployment and supply resilience

Regional dynamics exert a powerful influence on clinical development strategies, supply chain design, and reimbursement approaches for PMO conjugates. In the Americas, strong clinical trial infrastructure and a receptive regulatory environment for innovative modalities facilitate rapid proof-of-concept studies and close engagement with payers on value-based reimbursement pathways. Sponsors operating in this region often prioritize early regulatory interactions and real-world evidence planning to support broad access upon approval. In contrast, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization across jurisdictions and diverse pricing frameworks require nuanced market access strategies and tailored evidence packages to align with country-specific HTA processes.

Asia-Pacific is characterized by growing research capabilities, expanding manufacturing capacity, and evolving regulatory pathways that increasingly accept science-driven dossiers for novel modalities. Companies targeting this region often pursue partnerships with local manufacturers and contract facilities to shorten supply chains and address regional demand. Across all regions, clinical trial site selection, patient recruitment dynamics, and local regulatory expectations should inform program timelines and operational investments. By aligning regional strategies with global development plans, sponsors can optimize resource allocation while maintaining the flexibility to adapt to jurisdiction-specific requirements and opportunities.

Competitive and collaborative company-level insights that illuminate licensing, partnership, and manufacturing strategies adopted by stakeholders in the PMO conjugate ecosystem

Company strategies within the PMO conjugate ecosystem reveal a mix of competitive differentiation and collaborative partnership models. Early-stage innovators and academic spinouts often drive discovery and proof-of-concept data, leveraging deep biological insight and nimble experimentation to establish target validity. These organizations typically rely on partnerships with larger pharmaceutical companies or specialized contract development and manufacturing organizations to scale CMC operations and navigate late-stage clinical development. Larger biopharma companies bring commercial expertise, regulatory experience, and access to established distribution networks, which can accelerate patient access when integrated with innovative conjugation platforms.

Contract research and manufacturing organizations play a pivotal role by offering modular capabilities that span analytical development, GMP manufacturing, and clinical supply logistics. Strategic alliances, licensing deals, and joint ventures are common themes as companies seek to combine complementary capabilities-novel conjugation chemistry from small innovators with global development infrastructure from established sponsors. Investors and strategic partners increasingly look for clarity around CMC readiness, reproducible analytical methods, and a credible plan for long-term safety monitoring as prerequisites for engagement. Overall, successful corporate strategies balance proprietary science with pragmatic partner selection and robust operational plans to de-risk development pathways.

Clear, actionable steps industry leaders can take to optimize R&D pipelines, supply chains, regulatory engagement and commercialization for PMO conjugate portfolios

Industry leaders should adopt a set of actionable priorities that bridge scientific potential and commercial execution to realize the promise of PMO conjugates. First, prioritize platform robustness by investing in linker and conjugation chemistries that demonstrate consistent analytical performance and scalable manufacturability; this reduces downstream regulatory complexity and improves the predictability of supply. Second, embed regulatory and payer evidence generation early by designing clinical programs that capture both traditional efficacy endpoints and pragmatic measures of durability and patient-reported benefit, thereby smoothing the pathway to reimbursement discussions.

Third, diversify supply chains by qualifying multiple vendors for critical reagents and establishing regional manufacturing options to reduce exposure to policy-driven disruptions. Fourth, pursue strategic collaborations that align scientific capabilities with operational scale, for example pairing academic discovery teams with experienced CMO partners and commercialization-focused sponsors. Fifth, refine clinical development strategies around delivery mode and patient convenience, as intramuscular, intravenous, and subcutaneous routes impose different clinical site and patient adherence considerations. By sequencing these actions and assigning clear internal ownership, organizations can reduce technical and commercial risks while accelerating time to patient impact.

Robust research methodology detailing the mixed qualitative and quantitative approaches, expert validation and data triangulation used to underpin findings and recommendations

This analysis is grounded in a rigorous mixed-methods approach that combines primary qualitative engagement with subject-matter experts and quantitative synthesis of authoritative secondary materials. Primary inputs include structured interviews with senior R&D leaders, manufacturing experts, clinical investigators, and regulatory advisors who have direct experience with oligonucleotide and conjugate programs. These insights were synthesized with deep-dive reviews of peer-reviewed literature, regulatory guidance documents, and technical white papers to ensure alignment with current scientific understanding and precedent.

Data triangulation and cross-validation steps were applied to reconcile differing perspectives and validate thematic findings. Where appropriate, analytical frameworks were used to map supply chains, identify critical control points in CMC, and assess clinical development risk. The methodology emphasizes transparency and replicability, with traceable evidence trails and documented assumptions that support the report's conclusions and recommendations. Expert review panels provided final validation to ensure that interpretations are actionable and reflective of real-world operational constraints.

Synthesis of strategic takeaways emphasizing clinical, operational and policy levers that influence adoption, investor interest and long-term viability of PMO conjugates

In summary, PMO conjugates stand at an inflection point where scientific advances in targeting and delivery converge with evolving regulatory clarity and operational innovations in manufacturing. The modality offers compelling opportunities to address unmet needs across neuromuscular diseases, oncology, and rare genetic disorders, provided that sponsors align chemistry decisions, clinical strategies, and supply chain resilience with regulatory and payer expectations. Strategic segmentation that considers product type, application, end user, delivery mode, and molecule type helps prioritize investments and tailor development pathways to the most promising patient populations.

Practical next steps for stakeholders include strengthening platform reproducibility, engaging regulators and payers earlier in the development cycle, and establishing diversified manufacturing and sourcing strategies to mitigate policy and operational risks. By executing an integrated approach that harmonizes scientific rigor with pragmatic commercialization planning, organizations can enhance the likelihood of successful translation from bench to bedside while delivering meaningful clinical benefit to patients.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. PMO Conjugates Market, by Product Type

  • 8.1. Antibody PMO Conjugates
  • 8.2. Peptide PMO Conjugates

9. PMO Conjugates Market, by Application

  • 9.1. Neuromuscular Diseases
    • 9.1.1. Duchenne Muscular Dystrophy
    • 9.1.2. Spinal Muscular Atrophy
  • 9.2. Oncology
  • 9.3. Rare Genetic Disorders

10. PMO Conjugates Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Pharmaceutical & Biotechnology Companies

11. PMO Conjugates Market, by Delivery Mode

  • 11.1. Intramuscular
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. PMO Conjugates Market, by Molecule Type

  • 12.1. Multi Functional
  • 12.2. Single Functional

13. PMO Conjugates Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. PMO Conjugates Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. PMO Conjugates Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States PMO Conjugates Market

17. China PMO Conjugates Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. Alnylam Pharmaceuticals, Inc.
  • 18.7. Aurigene Pharmaceutical Services Ltd.
  • 18.8. Avidity Biosciences, Inc.
  • 18.9. Bio-Synthesis, Inc.
  • 18.10. Biogen Inc.
  • 18.11. BioMarin Pharmaceutical Inc.
  • 18.12. Creative Biogene Co., Ltd.
  • 18.13. Epichem Pty Ltd
  • 18.14. Gene Tools, LLC
  • 18.15. Ionis Pharmaceuticals, Inc.
  • 18.16. Merck KGaA
  • 18.17. NJ Bio, Inc.
  • 18.18. Novartis AG
  • 18.19. Pfizer Inc.
  • 18.20. PTC Therapeutics, Inc.
  • 18.21. Roche Holding AG
  • 18.22. Sarepta Therapeutics, Inc.
  • 18.23. Wave Life Sciences Ltd.
  • 18.24. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PMO CONJUGATES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PMO CONJUGATES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PMO CONJUGATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PMO CONJUGATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PMO CONJUGATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PMO CONJUGATES MARKET SIZE, BY ANTIBODY PMO CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PMO CONJUGATES MARKET SIZE, BY ANTIBODY PMO CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PMO CONJUGATES MARKET SIZE, BY ANTIBODY PMO CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PMO CONJUGATES MARKET SIZE, BY PEPTIDE PMO CONJUGATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PMO CONJUGATES MARKET SIZE, BY PEPTIDE PMO CONJUGATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PMO CONJUGATES MARKET SIZE, BY PEPTIDE PMO CONJUGATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PMO CONJUGATES MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PMO CONJUGATES MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PMO CONJUGATES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PMO CONJUGATES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PMO CONJUGATES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PMO CONJUGATES MARKET SIZE, BY RARE GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PMO CONJUGATES MARKET SIZE, BY RARE GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PMO CONJUGATES MARKET SIZE, BY RARE GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PMO CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PMO CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PMO CONJUGATES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PMO CONJUGATES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PMO CONJUGATES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PMO CONJUGATES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PMO CONJUGATES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PMO CONJUGATES MARKET SIZE, BY MULTI FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PMO CONJUGATES MARKET SIZE, BY MULTI FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PMO CONJUGATES MARKET SIZE, BY MULTI FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PMO CONJUGATES MARKET SIZE, BY SINGLE FUNCTIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PMO CONJUGATES MARKET SIZE, BY SINGLE FUNCTIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PMO CONJUGATES MARKET SIZE, BY SINGLE FUNCTIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PMO CONJUGATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PMO CONJUGATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. GCC PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. GCC PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. GCC PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 143. G7 PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. G7 PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NATO PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NATO PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. NATO PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NATO PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PMO CONJUGATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA PMO CONJUGATES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA PMO CONJUGATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA PMO CONJUGATES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA PMO CONJUGATES MARKET SIZE, BY NEUROMUSCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA PMO CONJUGATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA PMO CONJUGATES MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA PMO CONJUGATES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)